Anti-Human CD64 (FCGR1) (Clone 10.1) – Purified in vivo GOLD™ Functional Grade

Clone 10.1 is a monoclonal antibody targeting human CD64 (FcγRI), and its most common in vivo applications in mice involve identifying, characterizing, and functionally studying monocyte and macrophage populations, phenotyping immune cells, and evaluating antibody-mediated responses in humanized mouse models.

Key in vivo uses of clone 10.1 in mice include:

• Flow cytometry and functional studies for detecting human CD64 expression on monocytes, macrophages, dendritic cells, and activated granulocytes within humanized mouse models.
• Phenotyping and characterization of human immune cell populations after human hematopoietic cell engraftment or in the context of immune system reconstitution. This is especially important in humanized mice that contain human immune cells, allowing researchers to track and study their dynamics in vivo.
• Studying antibody-mediated effector functions: Clone 10.1 is sometimes used to block, activate, or monitor FcγRI-mediated pathways in experimental settings, such as inflammation, infection, autoimmune disease, or cancer models where human FcγRI plays a role. For these applications, functional grade and in vivo grade versions of the antibody are used.
• Preclinical therapeutic evaluation: In mice engineered to express human FcγRs (FcγRI), clone 10.1 facilitates assessment of monoclonal antibody therapies, especially those reliant on FcγRI-mediated effector functions, such as ADCC or phagocytosis, or tolerance/reactivity to human antibodies.

Important context:

• Clone 10.1 is specific for human CD64 and does not react with endogenous murine CD64; its in vivo applications thus require humanized or transgenic mice expressing human CD64.
• It is not typically used in standard wild-type mice unless they have been genetically modified to express human FcγRI.

Common experimental models:

• Humanized mouse models: Mice engrafted with human immune cells or genetically modified to express human CD64, enabling the study of human immune responses, autoimmune diseases, viral infections, anti-tumor immunity, and antibody-based therapies.
• Chronic antibody treatment studies: Used to monitor or modulate human CD64 in preclinical evaluation of monoclonal antibody therapies in cancer, infectious disease, or autoimmune disease models.

Alternate meanings:

• If asking about anti-mouse CD64 (rather than anti-human, clone 10.1), note that clone 10.1 is specific for human CD64 and is not used for mouse CD64 detection.
• There is also a clone 10.1 for indoleamine 2,3-dioxygenase in certain contexts, but in immunology, clone 10.1 almost universally refers to anti-human CD64.

Summary of main in vivo applications of clone 10.1 in mice:

• Identification and functional study of human monocytes/macrophages
• Phenotyping human leukocytes in humanized mouse models
• Functional modulation (blocking/activation) of human FcγRI pathways
• Preclinical testing of antibody therapies in mice expressing human FcγRI

These uses rely on mice with human immune components or transgenic expression of human CD64, not on wild-type mice.

The most commonly used antibodies or proteins combined with clone 10.1 (anti-CD64, FcγRI) in the literature are:

• CD14
• CD16
• HLA-DR
• CD45
• CD11b
• CD11c

These markers are frequently used alongside 10.1 to enable detailed analysis and phenotyping of monocyte and macrophage populations in immunological studies.

Additional details:

• These combinations are standard in flow cytometry panels for distinguishing between different monocyte subsets and for assessing activation or maturation states of myeloid cells.
• The pairing is especially common in both human immunology research and clinical applications, often in the context of inflammation, infection, or immune monitoring.
• 10.1 is also reported to be used for functional studies such as blocking FcγRI-mediated binding, and is compatible with a variety of other myeloid and leukocyte markers, depending on the experimental aim.

There is no significant evidence in the provided sources of consistent use of specific non-cellular proteins other than antibodies; the context is primarily multi-parametric antibody panels for cell phenotyping.

Clone 10.1 is a monoclonal antibody primarily used for recognizing human CD64 (Fc gamma receptor I/FcγRI), specifically the EC3 epitope of CD64. The key findings from scientific literature citing clone 10.1 are:

• Specificity and Utility: Clone 10.1 is highly specific for the EC3 domain of CD64, which is a high-affinity receptor for the Fc region of IgG. This specificity makes it a standard tool in immunophenotyping.
• Applications in Research: The antibody is widely used to identify and functionally characterize monocytes and macrophages in human samples, often in combination with other markers to phenotype myeloid cell populations.
• Functional Studies: Publications report the use of clone 10.1 in experiments requiring sensitive detection of FcγRI, aiding research on immune responses, inflammation, and autoimmune diseases.
• Commercial and Literature References: Several vendors reference foundational studies and review articles confirming the reliability and widespread usage of clone 10.1 in immunology and cell biology.

Additional details:

• CD64 is a 75 kDa transmembrane protein that binds the Fc portion of IgG with high affinity and is upregulated during certain immune responses.
• The antibody is available in various conjugated forms for flow cytometry and other detection methods.

In summary: The scientific literature consistently cites clone 10.1 as a robust monoclonal antibody for the identification, isolation, and study of CD64+ monocytes and macrophages, supporting its importance in immunological research and clinical studies.

Dosing regimens for clone 10.1 (anti-human CD64, FcγRI) are highly variable across different mouse models and depend on the model type, experimental objective, and antibody characteristics. There is no universally standardized regimen, as protocols are typically tailored to the specific immunological context and desired biological outcome in each study.

For example:

• Syngeneic tumor models, infection models, and humanized mouse strains may require different doses and schedules to achieve optimal target engagement and biological effect.
• Factors influencing regimen include mouse strain, disease state, immune status, and the pharmacokinetics (PK) of the antibody in each model.
• Dosing frequency often differs: some studies use more frequent dosing in mice (e.g., 2-3 times per week) due to increased antibody clearance, especially when administering human or chimeric antibodies that may be immunogenic in mice.
• Typical injection routes are intraperitoneal or intravenous, with dose amounts commonly reported in micrograms or mg/kg per mouse.

Without detailed published data specifically on clone 10.1 regimens in comparative mouse models, only general principles and practical guidance can be described:

• Investigators usually adapt dosing schedules based on pilot PK/PD studies to ensure adequate plasma and tissue concentrations and minimal immunogenicity.
• Common logic may apply a starting dose in the range of 100–250 µg per mouse or 1–10 mg/kg per injection, every 2–4 days, then adjust based on efficacy, toxicity, and PK findings—though the exact numbers should be confirmed for clone 10.1 in each specific experimental setting.

Summary:

• Dosing regimens for clone 10.1 in mice are not fixed and should be customized to the mouse model, experimental aim, and antibody characteristics.
• Researchers must optimize dose and schedule empirically for each situation; general ranges can guide initial experiments but should not replace direct optimization for the antibody and study system.

If you need example dosing protocols or PK data for clone 10.1 in specific mouse models (e.g., tumor, infection, humanized strain), additional targeted literature review or direct inquiry to suppliers may be required.